Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
Allogene Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 22, 2021
Allogene Therapeutics reported fiscal year 2020 executive compensation information on April 22, 2021.
In 2020, five executives at Allogene Therapeutics received on average a compensation package of $3.6M, a 43% decrease compared to previous year.
Average pay of disclosed executives at Allogene Therapeutics
David Chang, Chief Executive Officer, received $7.8M in total, which decreased by 30% compared to 2019. 84% of Chang's compensation, or $6.6M, was in option awards. Chang also received $506K in non-equity incentive plan, $675K in salary, as well as $83K in other compensation.
Rafael Amado, Chief Medical Officer, received a compensation package of $2.7M, which decreased by 64% compared to previous year. 47% of the compensation package, or $1.3M, was in option awards.
Eric Schmidt, Chief Financial Officer, earned $2.5M in 2020, a 28% decrease compared to previous year.
Alison Moore, Chief Technical Officer, received $2.5M in 2020, which decreases by 21% compared to 2019.
Veer Bhavnagri, General Counsel, earned $2.4M in 2020.
Related executives
You may also like
Source: SEC filing on April 22, 2021.